FDA approves expanded Camzyos label for Bristol Myers Squibb to treat obstructive HCM in patients weighing 30 kg or more

Bitget2026/09/30 21:32

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

FDA cleared an expanded label for Bristol Myers Squibb’s Camzyos to treat symptomatic obstructive hypertrophic cardiomyopathy in adults.
Decision adds pediatric patients weighing 30 kg or more, making Camzyos the only FDA-approved oHCM therapy for children.
Approval backed by Phase 3 SCOUT-HCM data showing a 48 mmHg greater reduction in Valsalva LVOT gradient versus placebo at week 28.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 202609301732BIZWIRE_USPR_____20260930_BW516104) on September 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

FDA approves expanded Camzyos label for Bristol Myers Squibb to treat obstructive HCM in patients weighing 30 kg or more

You may also like

Crypto prices